1. Introduction
===============

Most types of cancer, including breast cancer, originate from a small population of cancer stem cells (CSCs) \[[@B1-molecules-19-03149],[@B2-molecules-19-03149],[@B3-molecules-19-03149],[@B4-molecules-19-03149]\]. These CSCs are able to self-renew and give rise to other cancer cells that form a tumor mass \[[@B5-molecules-19-03149],[@B6-molecules-19-03149]\]. Breast cancer stem cells can be established from patients' surgical specimens, based on their ability to resist cell-detachment-induced apoptosis (anoikis) and to propagate *in vitro* as floating tumorspheres in suspension cultures \[[@B7-molecules-19-03149]\]. Tumorspheres show an increase in CSC population, overexpress neoangiogenic and cytoprotective factors, and display high tumorigenic potential in NOD/SCID mice \[[@B7-molecules-19-03149],[@B8-molecules-19-03149]\]. Established breast cancer cell lines also contain a small percentage of cancer stem cells that can be enriched in tumorsphere cultures \[[@B9-molecules-19-03149],[@B10-molecules-19-03149]\]. Therefore, suspension cultures of breast cancer cell lines have been used as a drug screening platform, and a number of reagents that target CSCs have been successfully identified \[[@B11-molecules-19-03149],[@B12-molecules-19-03149]\].

CSCs have been implicated in the resistance of cancer to conventional chemotherapy \[[@B13-molecules-19-03149],[@B14-molecules-19-03149]\], and likely play an essential role in metastasis \[[@B15-molecules-19-03149]\]. In addition, CSCs are relatively radioresistant, likely due to their heightened DNA repair \[[@B16-molecules-19-03149]\] and free-radical scavenging abilities \[[@B17-molecules-19-03149]\]. Conversely, radiation has been found to increase matrix metalloproteinases expression as well as migration and invasion in various cancer cell lines, including MCF-7 and MDA-MB-231 \[[@B18-molecules-19-03149],[@B19-molecules-19-03149],[@B20-molecules-19-03149],[@B21-molecules-19-03149]\].

5-Azacytidine (5-AzaC) and 5-aza-2\'-deoxycytidine (5-AzadC) are nucleoside analogues designed to reduce DNA methylation and have been used clinically for treating acute myelogenous leukemia \[[@B22-molecules-19-03149],[@B23-molecules-19-03149]\]. These cytidine analogues have diverse but overlapping effects on gene expression \[[@B24-molecules-19-03149]\], and on cellular survival \[[@B25-molecules-19-03149]\]. 5-AzaC has also been found to enhance the reprogramming efficiency of murine induced pluripotent stem cells by activating the expression of dormant genes \[[@B26-molecules-19-03149],[@B27-molecules-19-03149]\]. However, the effects of 5-AzaC on breast cancer stem cells have not been reported.

2. Results and Discussion
=========================

2.1. 5-Azacytidine Sensitizes MCF-7 Cells to Anoikis
----------------------------------------------------

To test the effects of 5-AzaC on the anoikis resistance of MCF-7 human breast cancer stem cells, we first examined the 48 h survival of MCF-7 suspension cells in the presence of 5 μM 5-AzaC. Equimolar amounts of actinomycin D and salinomycin \[[@B11-molecules-19-03149]\] served as the control for non-discriminatory cytotoxic agent and selective cancer stem cell inhibitor, respectively. Like salinomycin, 5-AzaC displayed selective toxicity toward suspended MCF-7 cells ([Figure 1](#molecules-19-03149-f001){ref-type="fig"}A). The dose-response study further confirmed the selective toxicity of 5-AzaC toward suspended cells, even at 50 μM ([Figure 1](#molecules-19-03149-f001){ref-type="fig"}B). EC~50~ was determined to be 8.014 μM using GraphPad Prism. The selective toxicity was due to the induction of anoikis, as 10 μM 5-AzaC induced the activation of caspase 7 and the degradation of poly ADP-ribose polymerase (PARP), and pan-caspase inhibitor Z-VAD-fmk significantly increased the survival of MCF-7 suspension cells treated with 5-AzaC ([Figure 1](#molecules-19-03149-f001){ref-type="fig"}C,D). In addition western blotting indicated that treatment of 5-AzaC for 24 h reduced the expression of breast stem cell maker CD44 and increased the expression of γ-H2AX, an indicator of DNA strand break in MCF7 suspension cultures ([Figure 1](#molecules-19-03149-f001){ref-type="fig"}E).

![(**A**) Effects of 5 μM actinomycin D, salinomycin, and 5-AzaC on the survival of MCF7 in attachment and suspension cultures (48 h). (**B**) 48 h survival curves of MCF-7 attachment and suspension cultures treated with 5-AzaC. (**C**) 5-AzaC (10 μM, 24 h) selectively induced the cleavage of caspase 7 and PARP in suspension MCF7 cells as determined by western blotting. (**D**) Pretreatment of 10 μM Z-VAD-fmk for 2 h increased the survival of MCF7 suspension cultures treated with 10 μM 5-AzaC for 48 h. (**E**) Expression of CD44 and γ-H2AX in MCF7 suspension cultures treated with 0--10 μM 5-AzaC for 24 h.](molecules-19-03149-g001){#molecules-19-03149-f001}

2.2. 5-AzaC Reduces the Clonogenicity of MCF-7 Cells
----------------------------------------------------

To determine if 5-AzaC inhibits MCF-7 CSC's ability to repopulate from single cells, we tested the effects of 5-AzaC on MCF-7 colony formation in 3-dimentional and monolayer culture conditions. 5-AzaC, as low as 0.1 μM, effectively inhibited the growth MCF-7 tumorspheres in suspension cultures ([Figure 2](#molecules-19-03149-f002){ref-type="fig"}A,B). 0.5 μM 5-AzaC also reduced the size of MCF-7 colonies embedded in soft agar ([Figure 2](#molecules-19-03149-f002){ref-type="fig"}C). Pretreatment of MCF-7 cells with 5-AzaC at concentrations higher than 0.5 μM for 24 h also reduced the clonal survival of MCF-7 cells in monolayer cultures ([Figure 2](#molecules-19-03149-f002){ref-type="fig"}D). 5-AzaC also inhibited tumorsphere formation of another breast cancer cell line T47D ([Figure 2](#molecules-19-03149-f002){ref-type="fig"}E).

![(**A**) Representative microphotographs of MCF-7 mammospheres grown in suspension culture with 0--0.5 μM 5-AzaC for 7 days. (**B**) The areas occupied by mammospheres from the digital microphotographs of 10 random visual fields were determined by ImageJ. Mean ± SD, *n* = 3; \*\* *p* \< 0.01 between control tumorspheres and the ones treated with 5-AzaC. (**C**) Representative microphotographs showing that 0.5 μM 5-AzaC reduced the size of 14 days MCF-7 3-dimentional colonies in soft agar assay. (**D**) 2-dimentional colony formation by adherent MCF-7 cells pre-treated with 0.05--20 μM 5-AzaC for 1 day. Each well was seeded with 1,000 viable cells which were cultured in the absence of 5-AzaC for two weeks, and then the colonies were visualized by crystal violet staining. (**E**) Inhibition of tumorsphere formation in 4 day T47D suspension cultures by 0.5 μM 5-AzaC.](molecules-19-03149-g002){#molecules-19-03149-f002}

2.3. 5-AzaC Inhibits the Migration and Metalloproteinase 9 Activity of MCF-7 Cells
----------------------------------------------------------------------------------

Previous reports have associated CSC properties with a strong propensity for tumor metastasis \[[@B28-molecules-19-03149]\], and increased cell mobility \[[@B29-molecules-19-03149]\]. We therefore tested the effects of 5-AzaC on the migration ability of and Metalloproteinase 9 (MMP-9) secretion in MCF-7 cells. 5-AzaC higher than 0.5 μM significantly inhibited the gap closure in the wound healing assay ([Figure 3](#molecules-19-03149-f003){ref-type="fig"}A). The activity of MMP9 in the supernatant of adherent MCF-7 cultures was also effectively inhibited by 10 μM 5-AzaC ([Figure 3](#molecules-19-03149-f003){ref-type="fig"}B). 5-AzaC also inhibited the migration of a more aggressive breast cancer cell line, MDA-MB-231 ([Figure 3](#molecules-19-03149-f003){ref-type="fig"}C).

![(**A**) Wound healing assay showing the inhibitory effect of 0.5--10 μM 5-AzaC on MCF-7 migration for 48 h. Mean ± SD, *n* = 3; \*\* *p* \< 0.01 between control and cells treated with 5-AzaC. (**B**) Metalloproteinase 9 activities in the supernatant of adherent MCF-7 cultures treated with 0 or 10 μM 5-AzaC for 24 h were determined by gelatin zymography. Results of triplicate experiments are shown. (**C**) Wound healing assay showing the inhibitory effect of 0.5--10 μM 5-AzaC on MDA-MB-231 migration for 36 h.](molecules-19-03149-g003){#molecules-19-03149-f003}

2.4. 5-AzadC Is Not Effective in Inducing MCF-7 Anoikis
-------------------------------------------------------

The effects of 5-AzadC, another cytidine analogue that can reduce DNA methylation, on MCF-7 anoikis was also tested and compared to that of 5-AzaC. 5-AzadC displayed very low cytotoxicity toward adhesion or suspension MCF-7 ([Figure 4](#molecules-19-03149-f004){ref-type="fig"}A,B). This suggests that the mechanisms involved in 5-AzaC's anti-cancer stem cell effects differ from 5-AzadC's.

![(**A**) 5-Azadeoxycytidine was not cytotoxic to either adhesion or suspension MCF-7 cells. (**B**) Comparison of the effects of 5-AzaC and 5-AzadC on the 48 h survival of suspension MCF-7 cells. Mean ± SD, *n* = 3; \*\* *p* \< 0.01 between cells treated with 5-AzaC or 5-AzadC.](molecules-19-03149-g004){#molecules-19-03149-f004}

2.5. 5-AzaC and Radiation Therapy Collaboratively Reduced the Growth of MCF-7 Tumorspheres
------------------------------------------------------------------------------------------

Since CSCs have been known to be more resistant to radiation, we further tested whether pretreating MCF-7 cells with 5-AzaC can sensitize MCF-7 CSCs to radiation with clinically relevant doses. MCF-7 tumorspheres were relatively resistant to 2 Gy radiation but showed reductions in number and size at 4 Gy, whereas MCF-7 cells pretreated with 5 μM 5-AzaC further showed significant reduction in tumorsphere growth ([Figure 5](#molecules-19-03149-f005){ref-type="fig"}).

![5-AzaC and radiation therapy collaboratively reduced the growth of MCF-7 tumorspheres. MCF-7 adhesion cultures were pretreated with 2.5 μM 5-AzaC for 1 day, irradiated with 0--4 Gy radiation, and then reseeded at 1000 cells/well in an ultralow attachment 96 well plate to allow tumorsphere formation for two weeks (left panel). Percent growth of tumorsphere was determined by WST-1 reagent (right panel). Mean ±SD, *n* = 3; \*\* *p* \< 0.01 between tumorspheres grown with or without 2.5 μM 5-AzaC.](molecules-19-03149-g005){#molecules-19-03149-f005}

In summary, we have demonstrated the effectiveness of 5-AzaC in suppressing the survival and growth of MCF-7 cancer stem cells in suspension cultures. This activity is not possessed by 5-AzadC, indicating the underlying mechanism may not be simply explained by global DNA demethylation. Interestingly, 5-AzaC significantly inhibited the clonogenicity and migration abilities of MCF-7 at 0.5 μM, much lower than needed to induce MCF-7 anoikis. This may suggest that 5-AzaC exerts its function by activating more than one signaling pathway.

3. Experimental
===============

3.1. Cell Culture
-----------------

Breast cancer cells were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum (FCS) and 0.1 mM nonessential amino acids at 37 °C in a humidified atmosphere (5% CO~2~). To culture CSCs and to propagate them as tumospheres, cells were suspended in DMEM--F12 supplemented with 0.4% bovine serum albumin, 5 μg/mL bovine insulin, 20 ng/mL basic fibroblast growth factor 2 (bFGF), and 10 ng/mL epidermal growth factor (EGF) at a density of 1,000 cells/mL in ultralow attachment 96 well plates. Fresh media were replenished every 3 days.

3.2. Assessment of Cellular Viability by Trypan Blue
----------------------------------------------------

Viability of dissociated cells was determined using a hemocytometer and the trypan blue dye exclusion method (final dye concentration: 0.04% *w/v*) \[[@B30-molecules-19-03149]\].

3.3. WST-1 Assay
----------------

WST-1 solution (Roche, Mannheim, Germany) was added to cells at 10 μL/100 μL medium and incubated for 4 h. The absorbance at 450 nm was measured for each well and the average reading of control cells was taken as 100% for normalization.

3.4. Tumorsphere Formation Assay
--------------------------------

As described previously \[[@B12-molecules-19-03149]\], the ability of cells of monolayer cultures to initiate tumorsphere formation were assessed by harvesting, washing, and resuspending monolayer cells in cancer stem cell medium (DMEM--F12 supplemented with 0.4% BSA, 20 ng/mL bFGF, 10 ng/mL EGF and 5 μg/mL insulin). Cells were then passed through a 40-μM sieve, counted, diluted, and seeded into 96-well ultralow attachment plates at 1,000 cells/well.

3.5. Soft Agar Colony Formation Assay
-------------------------------------

5 × 10^4^ cells were mixed with 2% molten low melting agarose in DMEM--F12 growth medium for a final concentration of 0.4% agarose. The cell mixture was placed on top of a solidified layer of 0.5% agarose with 1 × growth medium. Cells were fed every 6 to 7 days with growth medium \[[@B12-molecules-19-03149]\].

3.6. Clonogenic Assay
---------------------

After 5-AzaC pretreatment, the cells were reseeded at a density of 1 × 10^3^ cells per well in the 6-well culture plate and cultured for 10 to 15 days, with medium changed every 3 days. The colonies were then fixed with methanol-acetic acid (3:1) and stained with 1% crystal violet for 30 min at room temperature.

3.7. Wound-Healing Motility Assay
---------------------------------

Cells seeded onto six-well plates were allowed to grow to confluence before scratch wounds were created in each well using a p10 micropipette tip. The cells were washed three times with phosphate-buffered saline (PBS) and incubated with complete medium. Images of wound healing were captured by phase-contrast microscopy at indicated times after wounding.

3.8. Gelatin Zymography
-----------------------

Supernatants from cell cultures were collected, filtered through a 0.22 μM filter, and concentrated 50 × by using Centricon filters with 10 kD cutoff. Concentrated supernatants were denatured in 1 × non-reducing SDS gel sample buffer and applied without boiling to a 10% polyacrylamide gel containing 0.1% SDS and 1 mg/mL gelatin. After electrophoresis, the gels were washed in 50 mM Tris-HCl (pH 7.5) containing 0.15 M NaCl, 5 mM CaC1~2~, 5 μM ZnCl, 0.02% NaN~3~, 0.25% Triton X-100 at room temperature for 30 min three times, and then incubated in the same buffer without Triton X-100 at 37 °C for 20 h. The gelatin-clear zones were visualized by staining with Coomassie Brilliant Blue R-250 solution.

3.9. Western Blotting
---------------------

Western blotting was performed as described before \[[@B31-molecules-19-03149]\]. Antibodies used in this study are: Cleaved Caspase-7 (Asp198) (D6H1) Rabbit mAb \#8438, PARP Antibody \#9542, Cleaved PARP (Asp214) (D64E10) XP^®^ Rabbit mAb \#5625 from Cell Signaling Technology (Danvers, MA, USA); Anti-phospho-Histone H2A.X (Ser139) Antibody, clone JBW301 and Anti-CD44 \[H-CAM\] Antibody, clone EPR1013Y from Millipore (Billerica, MA, USA); γ-Tubulin Antibody (4D11) and Beta Actin Loading Control Antibody (BA3R) from ThermoFisher Scientific (Waltham, MA, USA).

3.10. Statistical Analysis
--------------------------

All experiments were repeated at least three times. Results are shown as the mean ± SD from three independent experiments. Data were analyzed by Student's T-test. *p* values \< 0.05 were considered statistically significant. Single and double asterisks indicate *p* \< 0.05 and *p* \< 0.01, respectively.

4. Conclusions
==============

Our results show that 5-AzaC effectively suppressed multiple aspects of MCF-7 human breast cancer stem cell activities: anoikis resistance, tumorsphere formation, and cellular migration capabilities.
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